CVG.STU CSPC PHARMACEUTICAL (CVG.SG)
- Market cap
- -
- P/E
- 11.0x
- P/B
- 1.97x
- ROE
- 11.7%
- Dividend yield
- 9.95%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is CVG.STU undervalued?
Graham numberThe Graham number of CSPC PHARMACEUTICAL (CVG.SG) cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CSPC PHARMACEUTICAL (CVG.SG) fundamental analysis
No fundamental analysis for CSPC PHARMACEUTICAL (CVG.SG) yet.
CSPC PHARMACEUTICAL (CVG.SG) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CSPC PHARMACEUTICAL (CVG.SG)
There is no Profile data available for CVG.SG.
Full company profileCSPC PHARMACEUTICAL (CVG.SG) financial statements
CSPC PHARMACEUTICAL (CVG.SG) annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 11.1B | 12.9B | 18.5B | 22.1B | 24.9B | 27.9B | 30.9B | 31.5B | 29.0B | 26.0B |
| Gross Profit | 5.65B | 7.81B | 12.2B | 15.9B | 18.7B | 21.1B | 22.3B | 22.2B | 20.3B | 17.1B |
| Operating Income | 2.37B | 2.91B | 3.99B | 4.60B | 6.06B | 6.25B | 6.76B | 7.02B | 5.48B | 4.18B |
| EBITDA | - | 3.52B | 4.69B | 5.35B | 7.21B | 7.72B | 8.66B | 8.53B | 6.96B | 6.26B |
| Net Income | 1.88B | 2.32B | 3.21B | 3.71B | 5.16B | 5.61B | 6.09B | 5.87B | 4.33B | 3.88B |
| EPS | - | 0.19 | 0.27 | 0.31 | 0.43 | 0.47 | 0.51 | 0.50 | 0.38 | 0.34 |
| Balance Sheet | ||||||||||
| Total Assets | 13.2B | 18.0B | 23.2B | 26.3B | 30.1B | 34.7B | 41.8B | 46.3B | 44.4B | 46.7B |
| Total Liabilities | 4.09B | 5.13B | 7.67B | 6.80B | 6.97B | 7.91B | 10.1B | 11.3B | 10.5B | 12.1B |
| Shareholders' Equity | 9.05B | 12.8B | 15.0B | 18.5B | 22.3B | 26.0B | 30.2B | 33.2B | 32.3B | 33.2B |
| Cash & Short-term Investments | 2.90B | 4.38B | 4.33B | 4.12B | 7.30B | 9.28B | 10.3B | 12.0B | 6.78B | 6.09B |
| Cash Flow | ||||||||||
| Operating Cash Flow | 2.61B | 2.75B | 3.89B | 3.78B | 6.74B | 4.64B | 7.63B | 4.18B | 4.53B | 5.83B |
| Capital Expenditure | 1.06B | 1.02B | 2.17B | 2.12B | 1.58B | 1.76B | 2.72B | 1.89B | 2.68B | 2.28B |
| Free Cash Flow | - | 1.73B | 1.72B | 1.66B | 5.16B | 2.88B | 4.90B | 2.29B | 1.86B | 3.55B |
| Ratios | ||||||||||
| ROE | 20.8% | 18.1% | 21.4% | 20.1% | 23.1% | 21.6% | 20.2% | 17.7% | 13.4% | 11.7% |
| ROA | 14.2% | 12.9% | 13.9% | 14.1% | 17.2% | 16.1% | 14.6% | 12.7% | 9.8% | 8.3% |
| Net Profit Margin | 17.0% | 17.9% | 17.4% | 16.8% | 20.7% | 20.1% | 19.7% | 18.7% | 14.9% | 14.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
CSPC PHARMACEUTICAL (CVG.SG) dividends
- Dividend yield
- 9.95%
- Forward dividend
- -
- Payout ratio
- 64.3%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 2.50B | 0.22 | 64.3% |
| 2024 | CNY 3.23B | 0.28 | 74.7% |
| 2023 | CNY 2.73B | 0.23 | 46.4% |
| 2022 | CNY 2.10B | 0.18 | 34.4% |
| 2021 | CNY 1.69B | 0.14 | 30.2% |
| 2020 | CNY 1.53B | 0.13 | 29.6% |
| 2019 | CNY 965M | 0.08 | 26.0% |
| 2018 | HKD 822M | 0.07 | 25.6% |
| 2017 | HKD 607M | 0.05 | 26.2% |
| 2016 | HKD 582M | - | 30.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 8:5 on Oct 15, 2020.
Who owns CSPC PHARMACEUTICAL (CVG.SG)
Ownership data of CSPC PHARMACEUTICAL (CVG.SG) is not available yet.
CSPC PHARMACEUTICAL (CVG.SG) company profile
- Company name
- CSPC PHARMACEUTICAL (CVG.SG)
- Ticker
- CVG.STU
- ISIN
- HK1093012172
- Exchange
- Stuttgart Exchange
- Sector
- Other
- Industry
- Metals & Mining
- Fiscal year end
- December
- Address
- Website
- -
About CSPC PHARMACEUTICAL (CVG.SG)
There is no Profile data available for CVG.SG.